Paper4606174
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.
Jaffe N and 3 others. N Engl J Med, 1974. Cited by 540 papers, by iCite.
Cite this record
ConductScience Library. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. Papers, record 4606174. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4606174
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Neoplasms | Major topic |
| Leucovorin | Major topic |
| Methotrexate | Major topic |
| Osteosarcoma | Major topic |
| Amputation, Surgical | |
| Clinical Trials as Topic | |
| Drug Therapy, Combination | |
| Femoral Neoplasms | |
| Follow-Up Studies | |
| Humans | |
| Injections, Intramuscular | |
| Injections, Intravenous | |
| Lung Neoplasms | |
| Neoplasm Metastasis | |
| Time Factors | |
| Vincristine |
Source PubMed
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 540 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40442778 | Targeting metastasis in paediatric bone sarcomas. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40442778 | PubMed |
| 40336661 | Prediction of High-Dose Methotrexate Blood Concentration in Osteosarcoma Patients Using Machine Learning. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/40336661 | PubMed |
| 40206491 | Post-treatment late and long-term effects in bone sarcoma: A scoping review. | J Bone Oncol | 2025 | https://conductscience.org/library/papers/40206491 | PubMed |
| 39941818 | Analysis and Historical Evolution of Paediatric Bone Tumours: The Importance of Early Diagnosis in the Detection of Childhood Skeletal Malignancies. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39941818 | PubMed |
| 38404899 | Bulk and single-cell sequencing identified a prognostic model based on the macrophage and lipid metabolism related signatures for osteosarcoma patients. | Heliyon | 2024 | https://conductscience.org/library/papers/38404899 | PubMed |
| 37505768 | Total Neoadjuvant vs. Standard Perioperative Cisplatin/ Doxorubicin Chemotherapy in Patients with Extremities Osteosarcoma: A Multi-Center Cohort Study. | Asian Pac J Cancer Prev | 2023 | https://conductscience.org/library/papers/37505768 | PubMed |
| 37460542 | Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37460542 | PubMed |
| 36900310 | Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS). | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36900310 | PubMed |
| 36814318 | Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis. | J Orthop Surg Res | 2023 | https://conductscience.org/library/papers/36814318 | PubMed |
| 36803784 | P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization. | J Transl Med | 2023 | https://conductscience.org/library/papers/36803784 | PubMed |
| 35163459 | Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163459 | PubMed |
| 33082842 | Transcriptome Analysis Identifies Novel Prognostic Genes in Osteosarcoma. | Comput Math Methods Med | 2020 | https://conductscience.org/library/papers/33082842 | PubMed |
| 32961800 | Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32961800 | PubMed |
| 32483726 | Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32483726 | PubMed |
| 32063749 | Construction of a circRNA-miRNA-mRNA network based on competitive endogenous RNA reveals the function of circRNAs in osteosarcoma. | Cancer Cell Int | 2020 | https://conductscience.org/library/papers/32063749 | PubMed |
| 31446435 | The Roles of Circular RNAs in Osteosarcoma. | Med Sci Monit | 2019 | https://conductscience.org/library/papers/31446435 | PubMed |
| 31083238 | Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation. | Medicine (Baltimore) | 2019 | https://conductscience.org/library/papers/31083238 | PubMed |
| 30732148 | Integrative analysis reveals driver long non-coding RNAs in osteosarcoma. | Medicine (Baltimore) | 2019 | https://conductscience.org/library/papers/30732148 | PubMed |
| 30483135 | Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30483135 | PubMed |
| 30378256 | A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2019 | https://conductscience.org/library/papers/30378256 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4606174
GET https://conductscience.org/api/papers/v1/4606174/cited_by?page=2